Candida antarctica lipase A and ortholog and application thereof

Through the contact of specific sn-2 selective lipase with fatty acids and secondary hydroxy fatty acids, the problem that the catalytic mechanism of Candida Antarctic lipase A is not fully understood, and the efficient synthesis of anti-inflammatory and anti-diabetic fatty acid esters is achieved, reducing the number of Waste, which improves synthesis efficiency, demonstrates thermal stability and selectivity.

CN119061082APending Publication Date: 2024-12-03WILMAR INTERNATIONAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410665568.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art has not yet fully understood the application and catalytic mechanisms of Candida Antarctic lipase A (CalA) and its homologues, and it is difficult to efficiently synthesize structured lipids, especially when alternative chemical synthesis involves hazardous solvents and harsh conditions.

Method used

Provided a method to produce fatty acid esters, specific amino acid sequences and nucleotide sequences are listed and expressed in the host using a specific sn-2 selective lipase through which it is contacted with a fatty acid and a secondary hydroxy fatty acid. In the bioreactor, the synthesis of various fatty acid hydroxyesters is realized.

Benefits of technology

It has achieved efficient synthesis of various fatty acid hydroxy esters, which have anti-inflammatory and anti-diabetic effects, reduce waste, improve synthesis efficiency, and demonstrate thermal stability and selectivity, which is suitable for the field of biotechnology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061082A_ABST
    Figure CN119061082A_ABST
Patent Text Reader

Abstract

Candida antarctica lipase A and orthologs are described herein. The lipase has sn-2 selectivity, and can be used to produce fatty acid esters by contacting the sn-2 selective lipase with a fatty acid and a secondary hydroxy fatty acid to produce the fatty acid esters. The lipase may be used to produce a compound of formula I by contacting an sn-2 selective lipase with a compound of formula II and a long chain fatty acid under suitable conditions to produce the compound of formula I. The sn-2 selective lipase may be isolated. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Singapore Patent Application No. 10202301529Y, entitled “Lipase”, filed on May 30, 2023, the entire contents of which are hereby incorporated by reference. A sequence listing of the amino acid sequences and nucleotide sequences described herein is provided in xml format together with this application, which is hereby incorporated by reference. Technical Field

[0002] The present invention relates to Candida Antarctica lipase A and orthologues and uses of these lipases. Background Art

[0001] Structured / modified lipids are specifically produced by changing the composition / positional distribution of fatty acids ( et al., 2020). For the synthesis of structured lipids, enzymes are preferred over chemical methods due to their selectivity (Osborn and Akoh, 2002). In addition, enzymatic synthesis also has greater potential for large-scale production in a more environmentally friendly manner, especially when alternative chemical synthesis involves hazardous solvents / harsh conditions (Arslan et al., 2020; Zhang et al., 2021). Some examples of structured lipids are estolides and human milk fat mimics (Cermak et al., 2017; Wei et al., 2020). For the synthesis of these lipids, promiscuous but selective lipases are usually used (Kapoor and Gupta, 2012).

[0002] A special group of lipases, namely Candida antarctica lipase A (CalA) and CalA-like lipases, have attracted attention in the field of biotechnology due to their unique selectivity and remarkable thermostability (Monteiro et al., 2021). However, the application and catalytic mechanism of CalA and CalA-like lipases are not yet fully understood. Summary of the invention

[0003] In one aspect, a method of producing fatty acid esters is provided. The method comprises providing a sn-2 selective lipase, wherein the sn-2 selective lipase comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 22 (CL20), SEQ ID NO: 82 (CL20), SEQ ID NO: 30 (CL28), SEQ ID NO: 90 (CL28), SEQ ID NO: 33 (CL31), SEQ ID NO: 93 (CL31), SEQ ID NO: 21 (CL19), SEQ ID NO: 81 (CL19), SEQ ID NO: 23 (CL21), SEQ ID NO: 83 (CL21), SEQ ID NO: 25 (CL23), SEQ ID NO: 85 (CL23), SEQ ID NO: 41 (CL39), SEQ ID NO: 101 (CL39), SEQ ID NO: 15 (CL13), SEQ ID NO: 75 (CL13), SEQ ID NO: 40 (CL38), SEQ ID NO: 100 (CL38), SEQ ID NO: 46 (CL44), SEQ ID NO: 5 NO:106 (CL44), SEQ ID NO:26 (CL24), SEQ ID NO:86 (CL24), SEQ ID NO:47 (CL45), SEQ ID NO:107 (CL45), SEQ ID NO:17 (CL15), SEQ ID NO:77 (CL15), SEQ ID NO:44 (CL42), SEQ ID NO:104 (CL42), SEQ ID NO:51 (CL49), SEQ ID NO:111 (CL49), SEQ ID NO:56 (CL54) and SEQ ID NO:116 (CL54); and contacting the sn-2 selective lipase with a fatty acid and a secondary hydroxy fatty acid to produce a fatty acid ester. The fatty acid and the secondary hydroxy fatty acid can be the same or different.

[0004] In one embodiment, when the fatty acid and the secondary hydroxy fatty acid are the same, this can produce a polymerized fatty acid ester. Advantageously, this can be used as a lubricant.

[0005] In another embodiment, the fatty acid and secondary hydroxy fatty acid are different and can be used to produce fatty acid esters at the secondary hydroxy position. It is believed that the palmitate of hydroxystearic acid has anti-inflammatory and anti-diabetic effects, and these esters may be related to diseases such as diabetes and chronic inflammation. Similar other fatty acid hydroxy esters may have similar properties.

[0006] In one embodiment, the sn-2 selective lipase consists essentially of the amino acid sequence, preferably, the sn-2 selective lipase consists of the amino acid sequence.

[0007] In one embodiment, the amino acid sequence is selected from the group consisting of SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:33 (CL31), SEQ ID NO:93 (CL31), SEQ ID NO:21 (CL19), SEQ ID NO:81 (CL19), SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:41 (CL39) and SEQ ID NO:101 (CL39).

[0008] In one embodiment, the fatty acid and the secondary hydroxy fatty acid are each independently a C14 to C22 fatty acid.

[0009] In one embodiment, the hydroxyl group in the secondary fatty acid is located at one of the following positions: C2, C10, C12, C15 and any combination thereof. The carboxylic acid in the fatty acid is C1, and the secondary hydroxyl position is calculated based on this.

[0010] In one embodiment, the secondary hydroxy fatty acid is a C16 hydroxy fatty acid or a C18 hydroxy fatty acid, preferably the secondary hydroxy fatty acid is hydroxystearic acid.

[0011] In one embodiment, the fatty acid is a C16 fatty acid or a C18 fatty acid, preferably the fatty acid is palmitic acid.

[0012] In an embodiment, providing the sn-2 selective lipase comprises expressing the corresponding nucleotide sequence in a host. Advantageously, the sn-2 selective lipase can be used directly in a bioreactor after expression, or for minimal separation of other components present in the bioreactor. The sn-2 selective lipase can be purified (if necessary).

[0013] Advantageously, the method enables the synthesis of a wide variety of fatty acid hydroxy esters and their use in a variety of different applications.

[0014] In one aspect, a method of producing a compound of Formula I is provided. The method comprises providing a sn-2 selective lipase; and contacting the sn-2 selective lipase with a compound of Formula II and a long chain fatty acid under suitable conditions to produce a compound of Formula I. Formula I is Formula II is R 1 It is the second alkyl tail of the second longest chain fatty acid, R 2 is an alkyl tail of a long-chain fatty acid, and the long-chain fatty acid and the second long-chain fatty acid are different long-chain fatty acids.

[0015] Advantageously, the method enables the selective attachment of fatty acids to the middle hydroxyl group (position 2) in triacylglycerides. The method provides an additional production route to produce a wide range of triacylglycerides and potentially new and unusual triacylglycerides.

[0016] In some embodiments, the sn-2 selective lipase comprises an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:44 (CL42), SEQ ID NO:104 (CL42), SEQ ID NO:15 (CL13), SEQ ID NO:75 (CL13), SEQ ID NO:47 (CL45), SEQ ID NO:107 (CL45), SEQ ID NO:2 (UMLA), SEQ ID NO:62 (UMLA), SEQ ID NO:1 (CalA), SEQ ID NO:61 (CalA), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:26 (CL24), SEQ ID NO: NO:86(CL24), SEQ ID NO:21(CL19), SEQ ID NO:81(CL19), SEQ ID NO:41(CL39), SEQ ID NO:101(CL39), SEQ ID NO:17(CL15), SEQ ID NO:77(CL15), SEQ ID NO:46(CL44), SEQ ID NO:106 (CL44), SEQ ID NO:51 (CL49), SEQ ID NO:111 (CL49), SEQ ID NO:33 (CL31) and SEQ ID NO:93 (CL31). Preferably, the amino acid sequence is selected from the group consisting of SEQ ID NO: 23 (CL21), SEQ ID NO: 83 (CL21), SEQ ID NO: 22 (CL20), SEQ ID NO: 82 (CL20), SEQ ID NO: 30 (CL28), SEQ ID NO: 90 (CL28), SEQ ID NO: 44 (CL42), SEQ ID NO: 104 (CL42), SEQ ID NO: 15 (CL13), SEQ ID NO: 75 (CL13), SEQ ID NO: 47 (CL45) and SEQ ID NO: 107 (CL45).

[0017] In an embodiment, the sn-2 selective lipase comprises an amino acid sequence. Preferably, the sn-2 selective lipase consists essentially of the amino acid sequence, more preferably, the sn-2 selective lipase consists of the amino acid sequence.

[0018] In an embodiment, the long-chain fatty acid and the second long-chain fatty acid are C14 to C22 fatty acids. Preferably, the long-chain fatty acid and the second long-chain fatty acid are C16 fatty acids or C18 fatty acids.

[0019] In an embodiment, the long-chain fatty acid is palmitic acid, and the second long-chain fatty acid is oleic acid, and the compound of formula I is 1,3-olein-2-palmitin. In an embodiment, the method also includes providing a sn-1,3 selective lipase; contacting the sn-1,3 selective lipase with tripalmitin and oleic acid, wherein contacting the sn-1,3 selective lipase with tripalmitin and oleic acid and contacting the sn-2 selective lipase with triolein and palmitic acid are carried out in a reactor. This allows the oleic acid and palmitic acid produced in their corresponding reactions to be used as reactants in another reaction, and reduces the amount of waste products, thereby improving overall efficiency. Preferably, the two reactions can be carried out simultaneously in a single reactor. Alternatively, it can be carried out in different reactions or in the same reactor in a telescoped sequence.

[0020] In an embodiment, the long chain fatty acid is oleic acid and the second long chain fatty acid is stearic acid, and the compound of Formula I is 1,3-distearoyl-2-oleoyl-glycerol.

[0021] In an embodiment, providing the sn-2 selective lipase comprises expressing the corresponding nucleotide sequence in a host. Advantageously, the sn-2 selective lipase can be used directly in a bioreactor after expression, or with minimal separation from other components present in the bioreactor. The sn-2 selective lipase can be purified (if necessary).

[0022] In one aspect, an isolated sn-2 selective lipase is provided, the sn-2 selective lipase comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22 (CL20), SEQ ID NO: 82 (CL20), SEQ ID NO: 30 (CL28), SEQ ID NO: 90 (CL28), SEQ ID NO: 33 (CL31), SEQ ID NO: 93 (CL31), SEQ ID NO: 21 (CL19), SEQ ID NO: 81 (CL19), SEQ ID NO: 23 (CL21), SEQ ID NO: 83 (CL21), SEQ ID NO: 25 (CL23), SEQ ID NO: 85 (CL23), SEQ ID NO: 41 (CL39), SEQ ID NO: 101 (CL39), SEQ ID NO: 15 (CL13), SEQ ID NO: 75 (CL13), SEQ ID NO: 40 (CL38), SEQ ID NO: 100 (CL38), SEQ ID NO: 46 (CL44), SEQ ID NO: NO:106(CL44), SEQ ID NO:26(CL24), SEQ ID NO:86(CL24), SEQ ID NO:47(CL45), SEQID NO:107(CL45), SEQ ID NO:17(CL15), SEQ ID NO:77(CL15), SEQ ID NO:44(CL42), SEQID NO:104 (CL42), SEQ ID NO:51 (CL49), SEQ ID NO:111 (CL49), SEQ ID NO:56 (CL54) and SEQ ID NO:116 (CL54).

[0023] Preferably, the amino acid sequence is selected from the group consisting of SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:44 (CL42), SEQ ID NO:104 (CL42), SEQ ID NO:15 (CL13), SEQ ID NO:75 (CL13), SEQ ID NO:47 (CL45), SEQ ID NO:107 (CL45), SEQ ID NO:33 (CL31), SEQ ID NO:93 (CL31), SEQ ID NO:21 (CL19), SEQ ID NO:81 (CL19), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:41 (CL39) and SEQ ID NO:101 (CL39).

[0024] Preferably, the isolated sn-2 selective lipase consists essentially of the amino acid sequence, preferably the lipase consists of the amino acid sequence.

[0025] In an embodiment, the lipase further comprises a purification tag, which is bound to the N-terminus or C-terminus of the amino acid sequence, preferably the N-terminus. Non-limiting examples of suitable purification tags include 6x His tag sequences, such as VMHHHHHH (SEQ ID NO: 183) and Strep II tags.

[0026] In another aspect, a method for separating, detecting and / or quantifying triglycerides using a liquid chromatography-mass spectrometry (LC-MS) system is described, the method comprising eluting a mixture containing triglycerides through a CHIRALPAK IG-3 column, wherein the mobile phase comprises isopropanol and acetonitrile; and detecting the molecular weight of each separated peak in the mixture. In an embodiment, the triglyceride is selected from the group consisting of triolein (OOO), 1,3-dioleyl-2-palmitylglycerol (OPO) isomers, 1,3-dipalmitoyl-2-oleylglycerol (POP) isomers, tripalmitin (PPP), tristearin (SSS), 1,3-distearoyl-2-oleoylglycerol (SOS), 1,2-distearoyl-3-oleoylglycerol (SSO / OSS), 1,3-dioleoyl-2-stearoylglycerol (OSO), 1,2-dioleoyl-3-stearoylglycerol (SOO / OOS) and trilaurin (LLL). In an embodiment, the mixture comprises at least two different triglycerides.

[0027] In another aspect, a method for separating, detecting and / or quantifying fatty acid esters of hydroxy fatty acids (FAHFAs) using a liquid chromatography-mass spectrometry (LC-MS) system is provided, the method comprising eluting a mixture comprising fatty acid esters of hydroxy fatty acids through a C8-bound silica column, wherein the mobile phase comprises isopropanol and acetonitrile, and a gradient in which the concentration of acetonitrile decreases over time when eluting the mixture; and detecting the molecular weight of each separated peak in the mixture. In an embodiment, the FAHFAs are 12-hexadecanoyloxyoctadecanoic acid (12-PAHSA). Description of the drawings (each figure)

[0028] Figure 1 The SSN of Pfam PF03585 is shown. On the left, the orthologs are divided into prokaryotes / eukaryotes with an alignment score of 75, and CalA is located in the small cluster marked by the box. On the right, the fungal lipase cluster is further separated, where CalA is located with an alignment score of 140. The Uniprot number of CalA is W3VKA4, while the UMLA is A0A0D1DXG7.

[0029] Figure 2 Shown is an expression vector for expressing CalA orthologs in Pichia pastoris. The RFP gene will be replaced by a combination of genetic elements including the AOX1 promoter, aMF secretion tag, the gene of interest, and the AOX1 terminator. The antibiotic Zeocin is used as a selection marker for E. coli and Pichia pastoris. The HIS4 gene encodes histidinol dehydrogenase, which makes the plasmid act as an auxotrophic marker in Pichia pastoris if the plasmid insertion does not utilize the AOX1 promoter / terminator.

[0030] Figure 3 The hydrolysis activity of CalA and orthologs towards triolein is shown as indicated by the presence of diolein on TLC. The numbers on the TLC plate indicate the lipase tested. Figure 3 The boxes in the figure indicate the 16 orthologs with hydrolytic activity.

[0031] Figure 4a Quantification of sn-2 selectivity (hydrolysis) based on LC-MS analysis of the ratio of 1,2-dienes to 1,3-dienes is shown. The higher the ratio, the higher the degree of hydrolysis at the 1,3 position.

[0032] Figure 4b Comparison of peaks in LC corresponding to RML, GCL1 and CalA is shown.

[0033] Figure 5 T of CalA and selected orthologs are shown mand T agg It can be seen that CalA has a higher T m and T agg , which corresponds to its good thermal stability.

[0034] Figure 6 A reaction scheme showing transesterification of a triacylglyceride at the 2-position is shown.

[0035] Figure 7a Shown is the OPO produced after 4 hours of reaction using immobilized CalA and RML enzymes. For RML, most of the product is POO, not OPO, indicating its high sn1,3 selectivity. Neg is a negative control, which showed no reaction. Figure 7b OPOs produced using immobilized CalA, CL20, CL23, and CL31 are shown. Figure 7c The ratio of OPO to OOP / POO of CL20, CL23 and CL31 relative to CalA is shown.

[0036] Figure 8 LC chromatograms of TAG and the separation of OPO, POP, SOS, and SSO isomers using Chiralpak-IG are shown. The left panel A shows the separation of OOO, OPO isomers, POP isomers, and PPP. The right panel B shows the separation of OOO, OSO isomers, SOS isomers, and SSS.

[0037] Figure 9a The esterification reaction between palmitic acid and hydroxystearic acid is shown.

[0038] Figure 9b LC-MS detection of various compounds in less than 6 minutes is shown along with total ion chromatograms of the different analytes.

[0039] Fig.10 Screening of selected CalA orthologs with n-hydroxylated stearic acid and palmitic acid at 50°C, 70°C and 90°C is shown.

[0040] Fig.11 The conversion of 12-PAHSA over different time periods is shown. For each lipase tested, the bar graph shows the percent conversion at 5 minutes, 10 minutes, 20 minutes, 40 minutes, 80 minutes, 160 minutes, and 320 minutes from left to right. TM ECR1030M and Lifetech TM ECR8806M immobilizes different enzymes. DETAILED DESCRIPTION

[0041] In the description herein, many specific details are set forth in order to allow a thorough understanding of various exemplary embodiments of the present invention. However, it will be appreciated by those skilled in the art that embodiments of the present invention may be implemented without some or all of these specific details. Embodiments described in the context of one of the methods or devices are similarly valid for the other methods or devices. Similarly, embodiments described in the context of the methods are similarly valid for the devices, and vice versa.

[0042] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0043] As used herein, the articles "a", "an", and "the" used with respect to a feature or element include reference to one or more features or elements. As used herein, the term "and / or" includes any one and all combinations of one or more associated listed items. As used herein, the terms "first", "second", and "third", etc., are used only as labels and are not intended to impose numerical requirements on their objects.

[0044] Where combinations are disclosed, each subcombination of the elements of the combination is also specifically disclosed and within the scope of the invention. Conversely, where different elements or groups of elements are disclosed, combinations thereof are also disclosed. Where any element of an invention is disclosed as having multiple alternatives, examples of the invention in which each alternative is excluded, either alone or in any combination with other alternatives, are also hereby disclosed; more than one element of an invention may have such exclusions, and all combinations of elements having such exclusions are disclosed herein.

[0045] When a numerical range is listed, it is understood that each intermediate integer value and each fraction thereof between the upper and lower limits listed in the range, as well as each subrange between these values, are also specifically disclosed. The upper and lower limits of any range may be independently included in or excluded from the range, and each range in which either, both, or both limits are not included is also included in the present invention. . When the value in question has inherent limitations, such as when a component can be present at a concentration of 0 to 100%, or when the pH of an aqueous solution can range from 1 to 14, those inherent limitations are specifically disclosed. When a numerical value is explicitly stated, it is understood that numerical values ​​of approximately the same amount or quantity as the stated value are also within the scope of the present invention, as are ranges based thereon.

[0046] Although these terms each have different meanings, the terms "including", "consisting of, and "consisting essentially of" may be used interchangeably throughout this application. The term "having" has the same meaning as "including", and may be replaced with the terms "consisting of" or "consisting essentially of.

[0047] The terms "polypeptide" and "protein" are used interchangeably herein and refer to polymers of amino acids, regardless of the length of the polymer; therefore, peptides, oligopeptides, and proteins are included in the definition of polypeptides. The term also does not specify or exclude chemical or post-expression modifications of the polypeptides of the present invention, although chemical or post-expression modifications of these polypeptides may be included or excluded as specific embodiments. Thus, for example, covalently linked polypeptide modifications including glycosyl groups, acetyl groups, phosphate groups, lipid groups, etc. are explicitly encompassed within the term polypeptide. In addition, polypeptides with these modifications may be designated as individual species to be included in or excluded from the present invention. Natural or other chemical modifications (such as those listed in the examples above) may occur at any position in the polypeptide, including the peptide backbone, amino acid side chains, and amino or carboxyl termini. It should be understood that the same type of modification may be present in the same or varying degrees at several sites of a given polypeptide. In addition, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, due to ubiquitination, they may be branched or unbranched cyclic. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, γ-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer RNA-mediated addition of amino acids to proteins, such as arginylation and ubiquitination. The definition also includes polypeptides containing one or more amino acid analogs (including, for example, non-naturally occurring amino acids, amino acids that occur naturally only in unrelated biological systems, modified amino acids from mammalian systems, etc.), polypeptides with substituted bonds, and other modifications known in the art, including both naturally occurring and non-naturally occurring.

[0048] The terms "sequence similarity", "sequence identity percentage" and "homology percentage" are used interchangeably herein to refer to comparisons between polynucleotides and polypeptides and are determined by comparing two optimally aligned sequences over a comparison window, wherein the polynucleotide or polypeptide sequence portion in the comparison window may contain additions or deletions (i.e., gaps) compared to a reference sequence (which does not contain additions or deletions) to achieve optimal alignment of the two sequences. The percentage can be calculated as follows: the number of matching positions is generated by determining the number of positions where the same nucleic acid base or amino acid residue appears in the two sequences, the number of matching positions is divided by the total number of positions in the comparison window, and the result is multiplied by 100 to generate the sequence identity percentage. Identity is assessed using any of the various sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are not limited to, TBLASTN, BLASTP, FASTA, TFASTA, CLUSTAL W, FASTDB [Pearson and Lipman, (1988), Proc. Natl. Acad. Sci. USA 85(8): 2444-2448; Altschul et al., (1990), J. Mol. Biol. 215(3): 403-410; Thompson et al. (1994), Nucleic Acids Res. 22(2):4673-4680; Higgins et al., (1996), Meth. Enzymol. 266:383-402; Altschul et al., (1993), Nature Genetics 3:266-272; Brutlag et al. (1990) Comp. App. Biosci. 6:237-24], the disclosures of which are incorporated by reference in their entirety. The percentage of sequence identity is also referred to as "% sequence identity" or "Seq ID relative to CalA (%) without Met" is obtained by aligning the amino acid sequence without methionine and the native secretion tag.

[0049] The term "alkyl" used alone or as part of a larger moiety, such as alkoxy, haloalkyl, arylalkyl, alkylamine, cycloalkyl, dialkylamine, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, etc., means a saturated straight chain, cyclic or branched aliphatic group. The term "alkyl tail" refers to the alkyl portion of a fatty acid excluding the carboxyl group.

[0050] As used herein, long chain fatty acids refer to carboxylic acids with an alkyl tail having 13 to 21 carbon atoms, in other words, fatty acids having 14 to 22 carbon atoms, including carboxylic acids. Long chain fatty acids can be saturated and unsaturated, odd or even, branched or unbranched, and can be substituted or unsubstituted. Some non-limiting examples of long chain fatty acids include: myristic acid (C14, 14:0), pentadecanoic acid (C15, 15:0), palmitic acid (C16, 16:0), heptadecanoic acid (C17, 17:0), stearic acid (C18, 18:0), arachidic acid (C20, 20:0), behenic acid (C22, 22:0), myristoleic acid (C14, 14:1(9)), palmitoleic acid (C16, 16:1(9)), hexadecenoic acid (C16, 16:1(6)), oleic acid (C18, 18:19)), elaidic acid (C18, 18:1(9t)), vaccenic acid (C18, 18:1(11t)), linoleic acid (C18, 18:1(11t)), linoleic acid (C20, 20:0), oleic acid (C22, 22:0), linoleic acid (C20, 20:0), ... Acid (C18, 18:2 (9, 12)), trans-linoleic acid (C18, 18:2 (9t, 12t)), alpha-linolenic acid (C18, 18:3 (9, 12, 15)), arachidonic acid (C20, 20:4 (5, 8, 11, 14)), eicosapentaenoic acid (C20, 20:5 (5, 8, 11, 14, 17)), erucic acid (C22, 22:1 (13)), docosahexaenoic acid (C22, 22:6 (4, 7, 10, 13, 16, 19)) and hydroxy fatty acids such as 2-hydroxystearic acid, 10-hydroxystearic acid, 12-hydroxystearic acid, 15-hydroxystearic acid and 2-hydroxypalmitic acid. Long chain fatty acids may be referred to as CX fatty acids, where X is the number of carbons in the fatty acid chain that includes the carboxylic acid.

[0051] The sn-2 selective lipase described herein is a lipase that preferentially reacts at the 2 position of triacylglycerol or glycerol, rather than the 1 position and the 3 position, or more generally, preferentially forms or cleaves (hydrolyzes) fatty acid esters with secondary hydroxyl groups. Based only on probability without considering spatial or electronic factors, the probability of non-selective lipases reacting at the 1 position and the 3 position is twice that of the 2 position reaction. In addition, due to spatial factors, the reactivity of secondary hydroxyl groups is much lower than that of primary hydroxyl groups. Therefore, the sn-2 selective lipase herein is a fatty ester, wherein the ratio of primary hydroxyl groups to secondary hydroxyl groups (e.g., hydrolysis or esterification) is 4:1 or lower, specifically, for triacylglycerol groups, the ratio of 1,3-hydroxyl groups to 2-hydroxyl groups (e.g., hydrolysis or esterification) is 8:1 or lower. Preferably, the ratios are 3:1 or lower and 6:1 or lower, respectively, more preferably, the ratios are 2:1 or lower and 4:1 or lower, respectively, and even more preferably, the ratios are 1:1 or lower and 2:1 or lower, respectively.

[0052] The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and use of the invention. In addition, there is no intention to be limited by any theory presented in the foregoing background technology of the invention or the following detailed description. Other technical advantages will become apparent to those of ordinary skill in the art after reviewing the following drawings and description.

[0053] The biotechnological potential of CalA and its orthologs is studied and described herein. Using the enzyme similarity tool (EFI-EST), a group of 58 orthologs (CL1 to CL58) of fungal lipases were identified and characterized. The sequences of CalA and 58 orthologs are shown in Table 3. SEQ ID NO:1 and SEQ ID NO:61 are peptide sequences of CalA without and with signal peptide, respectively. SEQ ID NO:2 and 62 are peptide sequences of Ustilago maydis lipase A (UMLA) without and with signal peptide, respectively. The peptide sequences of CalA orthologs (CL1 to CL58) are SEQ ID NO:3 to SEQ ID NO:60 and SEQ ID NO:63 to SEQ ID NO:120 without and with signal peptide, respectively. The CalA orthologs in this embodiment have similarities in sequence and function. Among the 58 orthologs, 16 can accept long-chain triacylglycerides, and most of them are thermostable. A notable feature of CalA is its sn-2 selectivity, although not outstanding (Monteiro et al., 2021). Investigation of the sn-2 selectivity of orthologs showed that six of them were more selective than CalA. Of the 16 orthologs identified, six had better sn-2 selectivity than CalA. A liquid chromatography mass spectrometry (LC-MS) method was developed to measure selectivity based on the ratio of 1,2-diolein and 1,3-diolein during hydrolysis of triolein. The sn-2 selectivity of the lipase may have implications as an alternative / complementary reaction to produce the human milk fat mimetic 1,3-olein-2-palmitin (OPO), also known as 1,3-dioleoyl-2-palmitoylglycerol.

[0054] Conventional OPO synthesis requires a sn-1,3 selective lipase to perform an acidolysis reaction using tripalmitin (from palm stearin) and oleic acid (Ferreira and Tonetto, 2017). Palmitic acid is a waste product as it is replaced by oleic acid during the reaction (Ferreira and Tonetto, 2017). Using an ideal sn-2 selective lipase, an acidolysis reaction using triolein (from high oleic sunflower oil) and palmitic acid (a waste product from conventional synthesis) will also produce OPO. In other words, a sn-2 selective lipase will selectively transesterify at the 2 position of the triacylglyceride instead of the 1,3 position, e.g. Figure 6 As shown. Therefore, using these two methods, a circular bioeconomy can be achieved by minimizing waste (waste from both methods becomes feedstock for the other method) (Leong et al., 2021). If both reaction methods can be completed in a single reactor (one-pot process), the hydrolyzed fatty acids produced in one reaction can be used as reagents for another transesterification reaction, which greatly reduces the amount of waste and improves the synthesis efficiency. Alternatively, the two methods can be carried out in a condensation reaction without purifying the intermediates. In order to quantify the levels of OPO and other triacylglycerides in the reaction, an LC-MS method using a chiral column was developed, which effectively separated various triacylglycerides in less than 40 minutes.

[0055] Another interesting property of CalA lipase is its ability to accept sterically hindered alcohols (Zhang et al. 2021). This remarkable property makes CalA the only commercially available lipase that can efficiently synthesize fatty acid esters of hydroxy fatty acids (FAHFAs) belonging to the lactide family (Riecan et al. 2022; Zhang et al. 2021). FAHFAs are a new class of lipids discovered in 2014 (Yore et al. 2014) that have shown promising results in the treatment of inflammation and diabetes (Yore et al. 2014). The discovery that CalA catalyzes such reactions has greatly advanced the synthesis of such lipids (Zhang et al. 2021). This progress is necessary because the functional roles of variants of such lipids have not yet been elucidated. In addition to CalA, orthologs of CalA may be able to synthesize FAHFAs and may open up the possibility of synthesizing other variants of FAHFAs. Two orthologs of CalA were found to be able to produce 12-hexadecanoyloxyoctadecanoic acid (12-PAHSA) in the presence of palmitic acid (PA) and 12-hydroxystearic acid (12-HSA). We developed an LC-MS method that can detect various compounds within 5 minutes, compared to the existing method in the literature using gas chromatography mass spectrometry (GC-MS) which takes 40 minutes (Zhang et al., 2021), thus being more cost-effective by reducing the time spent and reagents used.

[0056] CL20, CL23 and CL31 each have less than 80% sequence identity with CalA. The expression levels of CL20 and CL23 in Pichia pastoris are higher than that of CalA. In addition, CL20 and CL31 exhibit good heat resistance, and both remain functional after heat treatment at 90°C.

[0057] Materials and methods

[0058] Chemicals

[0059] Triolein, tripalmitin, 1,3-dioleoyl-2-palmitoylglycerol, 1,2-dioleoylglycerol, and 1,3-dioleoylglycerol were purchased from Sigma Aldrich (Steinheim, Germany). 1,2-Dioleoyl-3-palmitoylglycerol, 1,3-dipalmitoyl-2-oleoylglycerol, and 1,3-dipalmitoyl-2-oleoylglycerol were purchased from Larodan (Sweden). Acetonitrile (Hypergrade for LC-MS) and isopropanol (Hypergrade for LC-MS) were from Fisher Scientific (Wierth, Germany). Formic acid for LC-MS was from Merck (Darmstadt, Germany). Nucleodur Gravity-SB C18 column (150 mm x 3 mm, 3 μm) was from Macherey–Nagel (Düren, Germany), Luna 3 μm C8(2)100A, LC column 100 x 2 mm) was from Phenomenex (California, USA) and Chiralpak IG-3 (4.6 mm idx 250 mm, 3 μm) was from Daicel Corporation (Osaka, Japan).

[0060] Generation of sequence similarity networks (SSNs) and target selection

[0061] SSN graphs were generated using EFI-EST (https: / / efi.igb.illinois.edu / efi-est / ) and visualized using Cytoscape v3.7.2 (Zallot et al., 2019). Pfam PF03585 was used to generate SSNs because CalA (lipase A from Pseudozyma aphidis (uniprot: W3VKA4), SEQ ID NO: 61) is from this protein family. The targets were between 107 and 653 residues in length and were grouped into clusters with less than 35% shared sequence identity between them. These nodes were grouped into their respective kingdoms (prokaryotes, eukaryotes, or archaea), and the alignment score was reduced to 75 so that smaller clusters of sequences from the same kingdom could be further investigated. The genes in the cluster where CalA is located were codon-optimized for expression in Pichia pastoris, synthesized and cloned into the pFAi2 vector with AOX1 promoter, α mating factor pre-region (aMFpre) and AOX1 terminator. All genes were synthesized without the innate signal sequence. The nucleotide sequences used to prepare the peptides are shown in SEQ ID NOs: 121 to 180, corresponding to CalA, UMLA and CL1 to CL58, respectively, and are shown in Table 3.

[0062] Screening for active CalA orthologs

[0063] Figure 2 The expression vector used to express CalA orthologs in Pichia pastoris is shown. The protein is expressed under the AOX1 promoter and secreted through the α-mating factor pre-region (aMFpre) with the AOX1 terminator. After sequencing, the expression vector was first linearized with the Sac I restriction enzyme and then integrated into the AOX1 promoter region in the Pichia pastoris (GS115) genome by electroporation and plated on yeast peptone dextrose (YPD) agar containing 100 μg / mL zeocin.

[0064] To express proteins, Pichia colonies were grown overnight in buffered glycerol complex (BMGY) medium and transferred to a 10-fold increased volume of buffered methanol complex medium (BMMY) the next day. The cultures were then induced with 1% methanol every day for five consecutive days, and ampicillin (100 ug / mL) was added every other day to prevent bacterial contamination. Subsequently, 10 kDa The spent culture medium containing the secreted proteins was concentrated 10-fold using ultracentrifugal filters (Merck, Germany) and used for thin layer chromatography (TLC) analysis of the reactions.

[0065] Pichia pastoris is generally considered safe and as a eukaryote is capable of forming disulfide bonds with expressed proteins. Other host cells such as Yarrowia lipolytica and Saccharomyces cerevisiae are possible.

[0066] TLC provides a rapid test for screening lipases active on long-chain triacylglycerides (TAGs). In the screening assay, 2 μL of triolein and 1 μL of concentrated culture medium and enzyme were reacted at 37°C for 2 hours. Afterwards, 24 μL of isopropanol was added and vortexed to stop and dilute the reaction. Subsequently, 1 μL of sample was loaded onto a TLC plate and run with a hexane: diethyl ether: formic acid (80:20:2 v / v) solution and stained with iodine for visualization.

[0067] Expression and purification of a secreted lipase capable of accepting long-chain TAGs

[0068] The signal peptide is usually processed (cleaved) by the host (Pichia pastoris) by a signal peptidase. However, in some cases, the cleavage is not completely complete. The signal peptide usually does not affect the activity of the lipase.

[0069] In order to express and purify active enzyme, 6x His tags (VMHHHHHH, SEQ ID NO:183) are added to pFAi2 expression vector by golden gate assembly at the N-terminal of lipase sequence. Similarly, due to aMFpre secretion tag, protein will be secreted. Any other suitable purification tag can be used. Protein expression is carried out in 800mL BMMY culture to obtain enough purified proteins. In order to adjust the pH value of the culture medium used, 40mL of 2M Tris solution (pH not adjusted) is added to reach a pH value of 7-8. Culture medium is centrifuged at 4 ℃ with 6000rpm for 30 minutes using JLA 10.500 rotor in Beckman Coulter centrifuge, and then centrifuged at 4 ℃ with 20,000rpm for 15 minutes using JA25.5 rotor in Beckman Coulter centrifuge. Then filter the supernatant with 0.2 μm filter paper, then use Akta pure 25FPLC to use HisTrap HP, 5mL column to purify. The equilibration and / or washing buffer consisted of 20 mM Tris (pH 8), 100 mM sodium chloride, 40 mM imidazole, and the elution buffer consisted of 20 mM Tris (pH 8), 100 mM sodium chloride and 250 mM imidazole. The eluted protein was desalted by gel filtration. The concentration of the protein was measured based on the absorbance reading at 280 nm.

[0070] Any other affinity tag may be used, such as a Strep II tag. However, in industrial production, a 6xHis tag may not be necessary, as the enzyme will be produced in a bioreactor and subsequent purification of the protein is not needed / required.

[0071] Proteins used for characterization contained a methionine (ATG) after cleavage of the secretion tag in Pichia pastoris. Proteins used for sn-2 selectivity, thermostability, OPO and FAHFA production contained a 6x His tag sequence VMHHHHHH (SEQ ID NO: 183) (GTGATGcatcatcaccaccatcac, SEQ ID NO: 184) at the N-terminus.

[0072] Determination of thermal stability

[0073] The melting temperature (T m ) is used to measure the thermal stability of enzymes. Using differential scanning fluorimetry, protein unfolding due to increased temperature can be detected based on the fluorescence shift of intrinsic tryptophan / tyrosine residues. Using UNcle (Unchained Labs), 9 μL of purified protein (>1 mg / ml) was loaded into the quartz wells in triplicate. Then, after the wells were sealed in an aluminum thermal transfer holder, the wells were loaded. The samples were heated from 20°C to 95°C at a rate of 0.3°C / min. Fluorescence spectra were obtained from 250 to 720nm at 0.8 times / sec. UNcle analysis software was used to calculate T using the centroid average method. m .

[0074] Sn-2 selectivity and detection

[0075] The regioselectivity of lipases can be determined by triolein hydrolysis (Robles-Machuca et al., 2019). If the lipase is non-regioselective, the ester bond of triolein will be cleaved indifferently, forming two 1,2-diolein molecules and one 1,3-diolein molecule (Cambon et al., 2008). However, sn-2 lipases produce a higher ratio of 1,3-diolein to 1,2-diolein when hydrolyzing triolein. Similarly, sn-1,3 lipases produce a higher ratio of 1,2-diolein to 1,3-diolein. In existing methods, diolein isomers are quantified by measuring the intensity of the TLC bands of the compounds after staining with copper acetate in water and phosphoric acid (50:50 v / v) (Robles-Machuca et al., 2019; Velasco-Lozano et al., 2012). Although TLC provides a rapid screen for lipase activity, it is not as reliable as liquid chromatography-mass spectrometry (LC-MS), which provides greater sensitivity and reliability for the identification of individual lipid species (Cajka and Fiehn, 2014).

[0076] However, the separation of 1,2-diolein and 1,3-diolein by LC-MS has been a challenge as there are no published or widely available methods that can effectively separate diolein isomers in LC-MS. A method from a recently published article that proposed the possibility of separating diolein isomers was tested to no avail (Schick et al., 2021). Therefore, a method for effectively separating diolein isomers in LC-MS was developed and described herein. To measure the hydrolysis activity of triolein-active lipase, 2 μL of 10 mg / mL triolein dissolved in hexane, 50 μL of 100 mM MOPS buffer (pH 7.2), 38 μL of water, and 10 μL of enzyme were used at a concentration such that less than 20% of the reaction was carried out within 15 minutes at 40°C and stirred at 800 rpm. After incubation, 200 μL of 0.9% sodium chloride in water was added, followed by 200 μL of n-hexane, followed by vortexing and centrifugation at 15000 g for 2 minutes. The top layer (in n-hexane) was extracted and transferred to a new tube. The process of adding hexane was repeated twice more, and then the hexane was dried using SpeedVac (Concentrator plus, Hamburg Eppendorf, Germany). The contents were then diluted in isopropanol: chloroform (49:1 v / v) for measurement.

[0077] The amount of diolein was measured using a liquid chromatography-mass spectrometry (LC-MS) system. The diolein can be 1,2-diolein or 1,3-diolein. The parameters and elution gradient of the LC are able to elute the diolein isomers more effectively, as shown in Table 1 below. Reverse phase chromatography was performed on a Nucleodur Gravity-SB C18 column (150 mm x 3 mm, 3 μm), using 0.1% formic acid in acetonitrile as solvent A and 1 mM ammonium formate in isopropanol as solvent B. The flow rate was 0.4 ml / mL throughout, and the column temperature was adjusted to 50°C. From 0 to 1 minute, the column was equilibrated with 100% solvent A, and then added dropwise to 85% solvent A from 1 to 1.2 minutes. From 1.2 minutes to 10 minutes, solvent A dropped to 83%, and further dropped to 82% after 2.5 minutes. From 12.5 minutes to 14 minutes, solvent A dropped from 82% to 40%. Solvent A was further reduced to 20% for 3 minutes. From 17 to 18 minutes, solvent A was dropped to 10% and maintained for another 2 minutes. Finally, from 20 minutes to 20.5 minutes, solvent A was increased back to 100%. The injection volume was 1-2 μL, and the measurement was performed in positive mode using DualAJS ESI. The gas temperature was 280°C, the drying gas rate was 15 L / min, the nebulizer pressure was 40 psi, the sheath gas temperature was 300°C, and the sheath gas flow rate was 12 L / min. Table 1. LC parameters for separation of 1,2- and 1,3-diolein

[0078] Detection of triglycerides using liquid chromatography-mass spectrometry (LC-MS)

[0079] The TAG solution (2 μL) was injected into an Agilent 1290 Infinity UHPLC (Agilent Technologies, Waldbronn, Germany) with a CHIRALPAK IG-3 column (4.6 mm id x 250 mm, 3 μm) (Daicel Corporation), which was maintained at 30° C. throughout the analysis. TAG was separated isocratically at a flow rate of 0.5 mL / min using 98% solvent A (acetonitrile) and 2% solvent B (90% isopropanol, 10% acetonitrile, 0.1% formic acid, and 1 mM ammonium formate) for 35 minutes. For batches containing SSS, SOS, SSO / OSS, OOS / SOO, and OSO, the run time was extended to 60 minutes. The LC system was coupled to an Agilent 6550iFunnel Q-TOF mass spectrometer (Agilent Technologies) equipped with a DualAJS ESI (Agilent Technologies, Waldbronn, Germany) for detection and quantification of TAGs. The MS was set in positive mode for detection and quantification. The drying gas temperature was set to 280 °C, the drying gas rate was set to 15 L / min, the nebulizer pressure was set to 40 psi, the sheath gas temperature was set to 300 °C, and the sheath gas flow rate was set to 12 L / min. For quantification, the m / z of PPP, OPP / PPO / POP, OPO / POO / OOP, OOO, OSO / OOS / SOO, SOS / SSO / OSS, and SSS were 824.7702, 850.7858, 876.8015, 902.8171, 904.8328, 906.8484, and 908.8641, respectively.

[0080] The use of ChiralPak IG-3 columns provides high precision quantification of OOP, OPO and POO. Advantageously, the TAG LC-MS method of the present embodiment can achieve better peak separation than existing methods.

[0081] Screening for CalA-like orthologs with triolein activity against 2-, 10-, 12-, and 15-PAHSA

[0082] To screen for lipases capable of producing FAHFAs, orthologs were expressed in BMGY Zeo under a constitutive GAP promoter with an aMFPre secretion tag, and expression was carried out in deep well blocks in a Glascol microplate shaker at 30°C, 800rpm and 70 pulses / second for four days. The supernatant containing the enzyme was preheated at 50°C, 60°C or 70°C for 1 hour and then reacted at 800rpm for 1 hour at the corresponding temperature using an Eppendorf SmartBlock DWP 1000 (Eppendorf, Germany). After preheating, 2.5 μL of 10 mg / mL palmitic acid and 5 mg / mL n-hydroxystearic acid (HSA) (n=2, 10, 12 or 15) dissolved in DMSO were added to 50 μL of the supernatant. After the reaction, the deep well block was centrifuged and an isopropanol solution of heptadecanoic acid was added as an internal standard. It was then placed in Automated extraction was performed in an ELISA 5070 (Eppendorf, Germany). It was found that 2-HSA has limited solubility in common organic solvents such as acetonitrile, dichloromethane, toluene, chloroform, and ethyl acetate, with solubility not exceeding 1 mg / mL. However, it is soluble in methanol. Therefore, the BUME method for the extraction process was adopted with some modifications (L. et al., 2012). The BUME method achieves liquid-liquid extraction, allowing the compounds of interest to be isolated from the enzyme-containing supernatant. For each reaction, 150 μL of a butanol:methanol (3:1) mixture was added to a 1 mL deep well block and stirred at 1000 rpm for 5 minutes. Subsequently, 150 μL of heptane:ethyl acetate (3:1) was added and also stirred at 1000 rpm for 5 minutes. Next, 150 μL of 0.9% sodium chloride was added and the mixture was mixed by pipetting, then sealed and centrifuged at 3000 x g for 1 minute. After centrifugation, a distinct bottom aqueous layer and top organic layer were observed. The deep well block was then placed back into the 5070 (Eppendorf, Germany), and 20 μL of the organic layer was added to a Greiner 96-well polypropylene plate (Greiner, Austria). 180 μL of isopropanol was added and mixed thoroughly to prepare for liquid chromatography-mass spectrometry (LC-MS) detection.

[0083] The FAFHA LC-MS method uses a C8 column, which can run for 5 minutes or less. In contrast, the run time for separating lipids using a C18 column can be up to 30 minutes. Therefore, the C8 column used in the FAHFA LC-MS method of this embodiment can increase experimental throughput and is suitable for use in the field of enzyme engineering.

[0084] Lipase immobilization and OPO biosynthesis

[0085] Lifetech TM ECR8806M was purchased from ECR Enzyme Immobilization Resins (Wales, UK). 50 μL of 40mM potassium phosphate buffer (pH 7) of 5mg support was immobilized on a small scale. Then, 50 μL of desalted purified enzyme was added to a final concentration of 20mM potassium phosphate. The suspension was stirred overnight at 18 ° C and 800 rpm in a thermomixer (Epend, Germany). The supernatant was removed and the protein concentration of the supernatant was measured to calculate the amount of fixed protein. The semi-dried support was then lyophilized and reacted.

[0086] To synthesize OPO, 10uL of small-scale reactants (a mixture of 4uL triolein: 1mg palmitic acid) were added to the immobilized enzyme. The reaction was maintained at 60°C and stirred continuously at 800rpm for 4 hours in a thermomixer (Epend, Germany). Subsequently, 250uL of hexane was added to dissolve the substrate and product, and then centrifuged at 10,000g for 2 minutes to precipitate the fixed beads. Then, 100uL of solution was taken out from the reaction tube to prevent further reaction. The contents of the reaction were then diluted in isopropanol: chloroform (49: 1v / v) to measure using LC-MS.

[0087] Lipase expression at bioreactor scale

[0088] CalA and CL20, CL23 and CL31 with high expression or high temperature tolerance were selected in 5L B bioreactor (Sartorius, Germany). The protocol for protein expression in Pichia pastoris developed by Invitrogen Corporation was adopted with some modifications (Invitrogen Corporation, 2022). For glycerol-fed batches, 100 mL of 50% glycerol was supplemented for 6 hours per 1 L of fermentation culture. When the dissolved oxygen reached its peak, 1 L of methanol was supplemented for four days per 1 L of starting fermentation volume. Due to the use of basal salt medium (BSM), the linearized plasmid integrated in GS115 (histidine-deficient) consists of functional HIS4 to ensure cell growth.

[0089] Lipase immobilization and 12-PAHSA biosynthesis reaction

[0090] Lifetech TM ECR8806M and Lifetech TM ECR1030M was purchased from ECR Enzyme Immobilization Resins (Wales, UK). The supernatant containing enzyme from the bioreactor is concentrated and buffer exchanged with 20mM sodium phosphate pH 7, 100mM NaCl. It is fixed, and the fixation uses 80ug protein (measured by Bradford assay) to one gram of fixed beads. The suspension is stirred continuously for one day at 4 ° C. Subsequently, the supernatant is removed, and the beads are washed with buffer before lyophilization. After lyophilization, 20.1 (± 0.17) mg beads are added to 62.5 mg of 12-hydroxystearic acid and 125 mg of palmitic acid. The mixture is then stirred at 70 ° C, 1000 rpm, and about 1uL of the mixture is taken out at different time points, diluted in hexane: isopropanol (1: 1v / v), and further diluted in isopropanol: chloroform (49: 1v / v), and injected into LC-TQ for analysis.

[0091] Detection of fatty acyl esters of hydroxy fatty acids (FAHFAs) using liquid chromatography-mass spectrometry (LC-MS)

[0092] The various compounds were detected and quantitatively analyzed using a liquid chromatography multi-sampler, which was an Agilent 1290 Infinity II multi-sampler (G7167B) (Agilent Technologies, Waldbronn, Germany) coupled to an Agilent 6495 triple quadrupole (Agilent Technologies) mass spectrometer. AJS ESI (Agilent Technologies, Waldbronn, Germany) was used as the source for ionizing the compounds. The MS was set in negative mode to detect the compounds. To separate the compounds, a Phenomenex Luna C8 (2) 100A column (3um, 100x 2mm) was used. The mobile phases A and B were water: methanol (1:4 v / v) and isopropanol containing 0.1% formic acid, respectively, and 1 μL of sample was injected. The flow rate was always set to 0.4 mL / min and the temperature was 50°C. The column was equilibrated with 100% A from 0 to 1 minute, then reduced to 30% A from 1 to 5 minutes, and then maintained for 3 minutes for elution. The drying gas temperature was 250°C, the drying gas rate was 15 L / min, the nebulizer pressure was 50 psi, the sheath gas temperature was 300°C, and the sheath gas flow rate was 11 L / min. The multiple reaction monitoring mode was used to measure each compound, as shown in Table 2 below.

[0093] Table 2.

[0094] Results and discussion

[0095] Sequence Similarity Network (SSN) of Fungal CalA-like Lipases

[0096] Candida antarctica lipase A (CalA) (SEQ ID NO: 61) has a highly divergent sequence compared to other hydrolases and is often described as a "special" enzyme (Monteiro et al., 2021; Robles-Machuca et al., 2019; Widmann et al., 2010). They are structurally different from common lipases and have only 15% sequence identity with the closest lipase family in Bacillus subtilis (Monteiro et al., 2021; Widmann et al., 2010). Interestingly, CalA exhibits selectivity and activity that are not common in other hydrolases. For example, CalA is thermostable, exhibits the ability to accept highly sterically hindered alcohols (secondary and tertiary alcohols), and has sn-2 selectivity, although not significant (Monteiro et al., 2021; Robles-Machuca et al., 2019). These interesting properties make CalA suitable for use in industry. However, the group of lipases to which CalA belongs is not well characterized and understood. The characterization of CalA orthologs is very useful to gain mechanistic insights for meaningful engineering modifications of this special family of lipases. Recently, Ustilago maydis lipase A (UMLA) SEQ ID NO:62) (Robles-Machuca et al., 2019) similar to CalA was characterized. Both lipases are from Pfam PF03585. In order to characterize and study the biotechnological potential of CalA orthologs, SSNs were created using EFI-EST. Templates close to CalA and UMLA were selected as described in the methodology, and they were all from Figure 1 There are 58 orthologs in total, as shown in Table 3.

[0097] Activity and expression of CalA-like lipase

[0098] 58 orthologs were found in Figure 2 The expression of α-glucose was carried out under the control of AOX1 promoter, aMFpre secretion tag and AOX1 terminator in the pFAi2 vector shown in FIG. Figure 3 As shown, among the 58 orthologs tested, 16 orthologs (by Figure 3 The boxes in the figure and the presence of diolein on TLC show hydrolytic activity against triolein (long-chain triacylglycerides). None of the lipases showed a significant sn-2 preference (single 1,3-diolein band). With the exception of some interesting singletons, such as CL13 and CL15, most of the active lipases were from the largest cluster similar to CalA and UMLA, such as Figure 1 As shown. Active lipases with sufficient protein expression were purified using a 6xHis tag located at the N-terminus, because the β-chain of CalA located at the C-terminus can be a lid that controls the entry of substrates into the lipase (Ericsson et al., 2008; Widmann et al., 2010). Among the 15 lipases, CL20 showed an abnormally increased lipase expression compared to CalA, while CL21, 23, and 28 showed similar protein expression profiles. The activity of the purified lipase towards triolein and its sn-2 selectivity were measured using LC-MS. As Figure 4a As shown, six of the orthologs (CL45, CL13, CL42, CL28, CL20, and CL21) showed enhanced sn-2 selectivity compared to CalA. CL38 and CL54 were not tested. The LC-MS method effectively separated 1,2-diolein and 1,3-diolein. The differences between the diolein profiles of the known enzymes are shown in Figure 4b , the known enzymes are CalA (sn-2 selective), Geotrichum candidum lipase 1 (GCL1) (SEQ ID NO: 182) (non-regioselective) and Rhizomucor miehei lipase (RML) (SEQ ID NO: 181) (sn-1,3 selective) (Laguerre et al., 2017; Palla et al., 2012; Robles-Machuca et al., 2019).

[0099] Thermostability of CalA-like lipases

[0100] In industrial processes, thermostable enzymes are necessary because enzymatic biosynthesis at high temperatures usually achieves better efficiency and economic performance (Domínguez de María et al., 2005). To determine the thermostability of lipases, the melting temperature (T m ) and the temperature at which lipase aggregates (T agg ). Comparison of the parameters will allow us to assess the thermal stability of the orthologs. Parameters used to measure the thermal stability of CalA orthologs are as follows Figure 5 All lipases were less thermostable than CalA and had similar T values ​​to CalA compared to all other tested orthologs. m and T agg Two lipases from CalA (CL21 and CL28) have high sequence identities with CalA (96.8% and 98.2%, respectively). m and T agg The ranges are 40°C to 77°C and 39°C to 69°C, respectively.

[0101] OPO biosynthesis

[0102] After immobilization, CalA was able to catalyze the reaction between palmitic acid and triolein at 60 °C. However, due to the lack of selectivity, a mixture of triacylglycerides was produced, such as Figure 7a However, CalA does show potential for the preparation of OPO if the selectivity can be improved compared to sn 1,3-lipase (RML) ( Figure 7a ).like Figure 7b and Figure 8 As shown in (Panel A), our LC-MS method efficiently separated various triglycerides involved in the biosynthesis of OPO using triolein and palmitic acid as starting materials. Immobilized CL20, CL23, and CL31 were also able to catalyze the reaction between palmitic acid and triolein at 60 °C, as shown in Figure 7b and Figure 7c As shown. Figure 7c In the results, it can be observed that CL20 produces OPO at a higher ratio than CalA, while CL23 and CL31 produce OPO at a lower ratio, which is consistent with Figure 4a In addition, the ability of the column to separate TAGs was extended to enzymatic synthesis of cocoa butter substitutes, especially 1,3-distearoyl-2-oleoyl-glycerol, and good separation resolution was also observed. The ability to effectively separate these TAG isomers and enantiomers provides a valuable tool for studying the regio- and enantioselectivity of lipases, providing important practicality for academic research and industrial applications in the bioproduction of structured lipids.

[0103] FAHFA Biosynthesis (Screening)

[0104] The biosynthesis of FAHFAs via esterification between free fatty acids and hydroxy fatty acids in the absence of water is considered optimal, as esterification is likely to be a thermodynamically controlled process (Zhang et al., 2021). Therefore, to remove water, the lipase needs to be immobilized on a support, coupled with subsequent lyophilization. However, immobilization requires sufficient amounts of enzyme, which is not easy to achieve for proteins expressed under shake flask conditions, at least in our study. Therefore, we developed an assay to evaluate the suitability of lipases for FAHFAs biosynthesis, taking into account factors such as expression yield, substrate solubility and availability, and throughput as described in Materials and Methods. In order to diversify the types of FAHFAs that can be synthesized by CalA and its orthologs, we chemically synthesized several hydroxylated stearic acid variants for screening, such as Figure 9aAs shown. To dissolve the substrates, we chose to use dimethyl sulfoxide (DMSO) because it effectively dissolves all relevant substrates and is suitable for use at higher temperatures (Byrne et al., 2016). Here, the presence of activity indicates that the lipase has the potential to qualitatively catalyze the biosynthesis of FAHFAs. Using this assay, we are also able to test a range of temperatures. Here, we tested the enzyme at three temperatures (50°C, 70°C, and 90°C). This choice reflects the known optimal activity temperature of CalA (50°C), the melting point of the substrates (palmitic acid and hydroxylated stearic acid) (70°C), and the goal of identifying enzymes with potential for future applications involving substrates with higher melting points (90°C) (Domínguez de María et al., 2005; Monteiro et al., 2021; Robles-Machuca et al., 2019). To evaluate the synthesis of FAHFAs, we developed an LC-MS method to detect and quantify n-FAHFAs and the corresponding reactants in less than 8 minutes, as Figure 9b This is an improvement over previous methods using gas chromatography-mass spectrometry (GC-MS), which previously required more than 40 minutes per run (Zhang et al., 2021).

[0105] In the screen for FAHFA biosynthesis, we included all CalA-like orthologs active on triolein, as well as randomly selected CL29, CL37, and CL40. In addition, GCL1 and RML, which are non-regioselective and sn1,3-regioselective lipases, respectively, were included. RFP was used as a negative control. Fig.10 As shown in the figure, all CalA orthologs active on triolein and GCL1 are able to synthesize at least one type of FAHFAs. CL29, CL37, and CL40 are unable to synthesize FAHFAs, possibly due to their limited ability to accept long-chain substrates, insufficient thermostability, or low enzyme expression. GCL1 is only active at 50°C, but inactive at 70°C and 90°C, probably because it cannot tolerate high temperatures. On the other hand, since RML is a sn1,3-regioselective lipase, RML is unable to synthesize FAHFAs, let alone target secondary alcohols of hydroxystearic acid.

[0106] 12-PAHSA biosynthesis

[0107] CalA is the only lipase discovered that biosynthesizes 12-PAHSA from 12-HSA and palmitic acid with high efficiency in the presence of organic solvents when immobilized (Zhang et al., 2021). Here, 12-PAHSA biosynthesis was performed in the absence of solvent using immobilized enzyme and substrates (12-hydroxystearic acid and palmitic acid) that melt at 70°C. Based on FAHFA screening, CL20, 23, and 31 were selected because they either expressed at high levels or exhibited thermostability (activity above 70°C). In terms of expression, CL20 and 23 showed higher expression levels compared to CalA and CL31 from the bioreactor according to the Bradford protein quantification assay. The enzymes were processed as described in the methods section and immobilized in the Lifetech TM ECR1030M and Lifetech TM In ECR8806. Fig.11 As shown, when immobilized, CL20, 23, and 31 were also able to synthesize 12-PAHSA, similar to CalA. Fig.11 The percentage conversion of 12-PAHSA is shown over time. Each group of histograms is an identified lipase and a resin used to immobilize the lipase. The histograms in each group are the percentage conversion after 5 minutes (min), 10 minutes, 20 minutes, 40 minutes, 80 minutes, 160 minutes and 320 minutes from left to right. The tested lipases can achieve more than 85% 12-PAHSA conversion in a solvent-free environment. In general, when comparing the same enzyme (on different fixed beads), ECR8806M is superior to ECR1030M in terms of initial conversion or the time required to reach 50% conversion.

[0108] In order to synthesize OPO using triolein and palmitic acid as substrates, several important factors must be considered, such as the ability to undergo acidolysis of long-chain triglycerides with fatty acids, high selectivity, and thermal stability, as the substrates need to melt at high reaction temperatures. Although CalA has the potential to be a candidate for OPO synthesis, its selectivity needs to be improved.

[0109] In addition, CalA and its orthologs showed good results in FAHFAs synthesis. These enzymes showed high thermostability and the ability to esterify long-chain fatty acids with secondary alcohol groups (on 12-HSA), which is rare in other hydrolases. Future studies will focus on determining the rate of FAHFAs synthesis and studying the substrate specificity of these enzymes. Table 3. Sequences without signal peptide

[0110] References

[0111] Arslan, A., Rancke-Madsen, A., & Brask, J. (2020). Enzymatic Synthesis of Estolides from Castor Oil. Catalysts, 10(8), 835. https: / / doi.org / 10.3390 / catal10080835

[0112] M., A., Hudecová, K., Kyselka, J., Filip, V., and Hrádková, I. (2020). Physical Properties of Structured Fats and Fat Blends Based on the Long Chain Fatty Acids. Food Biophysics, 15(1), 143–152. https: / / doi.org / 10.1007 / s11483-019-09609-8

[0113] Byrne, F. P., Jin, S., Paggiola, G., Petchey, TH. M., Clark, J. H., Farmer, T. J., Hunt, A. J., Robert McElroy, C., and Sherwood, J. (2016). Tools and techniques for solvent selection: Green solvent selection guides. Sustainable Chemical Processes, 4(1), 7. https: / / doi.org / 10.1186 / s40508-016-0051-z

[0114] Cajka, T., and Fiehn, O. (2014). Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. TrAC Trends in Analytical Chemistry, 61, 192–206. https: / / doi.org / 10.1016 / j.trac.2014.04.017

[0115] Cambon, E., Rodriguez, J. A., Pina, M., Arondel, V., Carriere, F., Turon, F., Ruales, J., and Villeneuve, P. (2008). Characterization of typo-, regio-, and stereo-selectivities of babaco latex lipase in aqueous and organic media. Biotechnology Letters, 30(4), 769–774. https: / / doi.org / 10.1007 / s10529-007-9603-3

[0116] Cermak, SC, Isbell, TA, Bredsguard, JW, and Thompson, TD (2017). Estolides. In Fatty Acids (page 475). Elsevier. https: / / doi.org / 10.1016 / B978-0-12-809521-8.00015-5

[0117] Domínguez de María, P., Carboni-Oerlemans, C., Tuin, B., Bargeman, G., van der Meer, A., and van Gemert, R. (2005). Biotechnological applications of Candida antarctica lipase A: State-of-the-art. Journal of Molecular Catalysis B: Enzymatic, 37(1–6), 36–46. https: / / doi.org / 10.1016 / j.molcatb.2005.09.001

[0118] Ericsson,DJ,Kasrayan,A.,Johansson,P.,Bergfors,T., AG, J.-E., and Mowbray, SL (2008). X-ray Structure of Candida antarctica Lipase A Shows a Novel Lid Structure and a Likely Mode of Interfacial Activation. Journal of Molecular Biology, 376(1), 109–119. https: / / doi.org / 10.1016 / j.jmb.2007.10.079

[0119] Ferreira, ML, and Tonetto, GM (2017). What Is The Importance of Structured Triglycerides and Diglycerides? In Enzymatic Synthesis of Structured Triglycerides. Springer International Publishing. https: / / doi.org / 10.1007 / 978-3-319-51574-8

[0120] Invitrogen Corporation. (2022). Pichia Fermentation Process Guidelines.

[0121] Kapoor, M., and Gupta, MN (2012). Lipase promiscuity and its biochemical applications. Process Biochemistry, 47(4), 555–569. https: / / doi.org / 10.1016 / j.procbio.2012.01.011

[0122] Laguerre,M.,Nlandu Mputu,M., B., Lopez, M., Villeneuve, P., and Dubreucq, E. (2017). Regioselectivity and fatty acid specificity of crude lipase extracts from Pseudozyma tsukubaensis, Geotrichum candidum, and Candidarugosa. European Journal of Lipid Science and Technology, 119(8), 1600302. https: / / doi.org / 10.1002 / ejlt.201600302

[0123] Leong, HY, Chang, C.-K., Khoo, KS, Chew, KW, Chia, SR, Lim, JW, Chang, J.-S., and Show, PL (2021). Waste biorefinery towards a sustainable circular bioeconomy: A solution to global issues. Biotechnology for Biofuels, 14(1), 87. https: / / doi.org / 10.1186 / s13068-021-01939-5

[0124] J., T., Oschmann, M., Svedendahl Humble, M., and J. (2019). Transesterification of a Tertiary Alcohol by Engineered Candida antarctica Lipase A. ChemBioChem, 20(11), 1438–1443. https: / / doi.org / 10.1002 / cbic.201800792

[0125] L., M., Forsberg, G.-B., Saarinen, S., Nilsson, R., and Hansson, G.I. (2012). The BUME method: A novel automated chloroform-free 96-well total lipid extraction method for blood plasma. Journal of Lipid Research, 53(8), 1690–1700. https: / / doi.org / 10.1194 / jlr.D023036

[0126] Monteiro,RRC,Virgen-Ortiz,JJ,Berenguer-Murcia, da Rocha, TN, dos Santos, JCS, Alcántara, AR, and Fernandez-Lafuente, R. (2021). Biotechnological relevance of the lipase A from Candida antarctica. Catalysis Today, 362, 141–154. https: / / doi.org / 10.1016 / j.cattod.2020.03.026

[0127] Osborn, HT, and Akoh, CC (2002). Structured Lipids-Novel Fats with Medical, Nutraceutical, and Food Applications. Comprehensive Reviews in Food Science and Food Safety, 1(3), 110–120. https: / / doi.org / 10.1111 / j.1541-4337.2002.tb00010.x

[0128] Palla, C. A., Pacheco, C., and Carrín, M. E. (2012). Production of structured lipids by acidolysis with immobilized Rhizomucor miehei lipases: Selection of suitable reaction conditions. Journal of Molecular Catalysis B: Enzymatic, 76, 106–115. https: / / doi.org / 10.1016 / j.molcatb.2011.11.022

[0129] Riecan, M., Paluchova, V., Lopes, M., Brejchova, K., and Kuda, O. (2022). Branched and linear fatty acidesters of hydroxy fatty acids (FAHFAs) relevant to human health. Pharmacology and Therapeutics, 231, 107972. https: / / doi.org / 10.1016 / j.pharmthera.2021.107972

[0130] Robles-Machuca,M.,del Campo,MM,Camacho-Ruiz,M. Ordaz, E., Zamora-González, E. O., Müller-Santos, M., and Rodríguez, J. A. (2019). Comparative features between recombinant lipases CALA-like from U. maydis and CALA from C. antarctica inthermal stability and selectivity. Biotechnology Letters, 41(2), 241–252. https: / / doi.org / 10.1007 / s10529-018-2630-4

[0131] Schick, D., Link, K., Schwack, W., Granvogl, M., and Oellig, C. (2021). Analysis of mono-, di-, triacylglycerols, and fatty acids in food emulsifiers by high-performance liquid chromatography–mass spectrometry. European Food Research and Technology, 247(4), 1023–1034. https: / / doi.org / 10.1007 / s00217-021-03684-3

[0132] Velasco-Lozano, S., Rodríguez-González, J. A., Mateos-Díaz, J. C., Reyes-Duarte, D., and Favela-Torres, E. (2012). Catalytic profiles of lipolytic biocatalysts produced by filamentous fungi. Biocatalysis and Biotransformation, 30(5–6), 459–468. https: / / doi.org / 10.3109 / 10242422.2012.740475

[0133] Wei, W., Sun, C., Wang, X., Jin, Q., Xu, X., Akoh, C. C., and Wang, X. (2020). Lipase-Catalyzed Synthesis of Sn-2 Palmitate: A Review. Engineering, 6(4), 406–414. https: / / doi.org / 10.1016 / j.eng.2020.02.008

[0134] Widmann, M., Juhl, PB, and Pleiss, J. (2010). Structural classification by the Lipase Engineering Database: A case study of Candida antarctica lipase A. BMC Genomics, 11(1), 123. https: / / doi.org / 10.1186 / 1471-2164-11-123

[0135] Yore, MM, Syed, I., Moraes-Vieira, PM, Zhang, T., Herman, MA, Homan, EA, Patel, RT, Lee, J., Chen, S., Peroni, OD, Dhaneshwar, AS, Hammarstedt, A., Smith, U., McGraw, TE, Saghatelian, A., and Kahn, BB (2014). Discovery of a Class of Endogenous Mammalian Lipidswith Anti-Diabetic and Anti-inflammatory Effects. Cell, 159(2), 318–332. https: / / doi.org / 10.1016 / j.cell.2014.09.035

[0136] Zallot, R., Oberg, N., and Gerlt, J. A. (2019). The EFI Web Resource for Genomic Enzymology Tools: Leveraging Protein, Genome, and Metagenome Databases to Discover Novel Enzymes and Metabolic Pathways. Biochemistry, 58(41), 4169–4182. https: / / doi.org / 10.1021 / acs.biochem.9b00735

[0137] Zhang, Y., Eser, BE, and Guo, Z. (2021). ABi-Enzymatic Cascade Pathway towards Optically Pure FAHFAs. ChemBioChem, 22(12), 2146–2153. https: / / doi.org / 10.1002 / cbic.202100070

Claims

1. A method for producing fatty acid esters, the method comprising: Provided is a sn-2 selective lipase comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:22(CL20), SEQ ID NO:82(CL20), SEQ ID NO:30(CL28), SEQ ID NO:90(CL28), SEQ ID NO:33(CL31), SEQ ID NO:93(CL31), SEQ ID NO:21(CL19), SEQ ID NO:81(CL19), SEQ ID NO:23(CL21), SEQ ID NO:83(CL21), SEQ ID NO:25(CL23), SEQ ID NO:85(CL23), SEQ ID NO:41(CL39), SEQ ID NO:101(CL39), SEQ ID NO:15(CL13), SEQ ID NO:75(CL13), SEQ ID NO:40(CL38), SEQ ID NO: 100 (CL38), SEQ ID NO: 46 (CL44), SEQ ID NO: 106 (CL44), SEQ ID NO: 26 (CL24), SEQ ID NO:86(CL24), SEQ ID NO:47(CL45), SEQ ID NO:107(CL45), SEQ ID NO:17(CL15), SEQ ID NO:77(CL15), SEQ ID NO:44(CL42), SEQ ID NO:104(CL42), SEQ ID NO:51(CL49), SEQ ID NO:111(CL49), SEQ ID NO:56(CL54) and SEQ ID NO:116(CL54); and The sn-2 selective lipase is contacted with fatty acids and secondary hydroxy fatty acids to produce fatty acid esters.

2. The method of claim 1, wherein: The sn-2 selective lipase essentially consists of the amino acid sequence, preferably, the sn-2 selective lipase consists of the amino acid sequence.

3. The method according to claim 1 or 2, wherein: The amino acid sequence is selected from the following group: SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:33 (CL31), SEQ ID NO:93 (CL31), SEQ ID NO:21 (CL19), SEQ ID NO:81 (CL19), SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:41 (CL39) and SEQ ID NO:101 (CL39).

4. The method according to any one of claims 1 to 3, wherein: The fatty acid and the secondary hydroxy fatty acid are each independently a C14 to C22 fatty acid.

5. The method according to any one of claims 1 to 4, wherein: The hydroxyl group in the secondary fatty acid is located at one of the following positions: C2, C10, C12, C15, and any combination thereof.

6. The method according to any one of claims 1 to 5, wherein: The secondary hydroxy fatty acid is a C16 hydroxy fatty acid or a C18 hydroxy fatty acid, and preferably the secondary hydroxy fatty acid is hydroxystearic acid.

7. The method according to any one of claims 1 to 6, wherein: The fatty acid is C16 fatty acid or C18 fatty acid, and preferably the fatty acid is palmitic acid.

8. The method according to any one of claims 1 to 7, wherein: Providing the sn-2 selective lipase includes expressing the corresponding nucleotide sequence in a host.

9. A method for producing a compound of formula I, the method comprising: Providing sn-2 selective lipase; and contacting a sn-2 selective lipase with a compound of formula II and a long chain fatty acid under suitable conditions to produce a compound of formula I, Wherein, Formula I is Formula II is R 1 It is the second alkyl tail of the second longest chain fatty acid, R 2 is the first alkyl tail of the long-chain fatty acid, and the long-chain fatty acid and the second long-chain fatty acid are different long-chain fatty acids.

10. The method of claim 9, wherein: The sn-2 selective lipase comprises an amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NO: 23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:44 (CL42), SEQ ID NO:104 (CL42), SEQ ID NO:15 (CL13), SEQ ID NO:75(CL13), SEQ ID NO:47(CL45), SEQ ID NO:107(CL45), SEQ ID NO:2(UMLA), SEQ ID NO:62(UMLA), SEQ ID NO:1(CalA), SEQ ID NO:61(CalA), SEQ ID NO:25(CL23), SEQ ID NO:85(CL23), SEQ ID NO:26(CL24), SEQ ID NO:86(CL24), SEQ ID NO:21(CL19), SEQ ID NO:81(CL19), SEQ ID NO:41(CL39), SEQ ID NO:101(CL39), SEQ ID NO:17(CL15), SEQ ID NO:77(CL15), SEQ ID NO:46(CL44), SEQ ID NO:106(CL44), SEQ ID NO:51(CL49), SEQ ID NO:111(CL49), SEQ ID NO:33(CL31) and SEQ ID NO:93(CL31).

11. The method of claim 10, wherein: The amino acid sequence is selected from the following group: SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:44 (CL42), SEQ ID NO:104 (CL42), SEQ ID NO:15 (CL13), SEQ ID NO:75 (CL13), SEQ ID NO:47 (CL45) and SEQ ID NO:107 (CL45).

12. The method according to claim 10 or 11, wherein: The sn-2 selective lipase comprises the amino acid sequence.

13. The method according to claim 10 or 11, wherein: The sn-2 selective lipase essentially consists of the amino acid sequence, preferably, the sn-2 selective lipase consists of the amino acid sequence.

14. The method according to claims 9 to 13, wherein: The long chain fatty acid and the second long chain fatty acid are C14 to C22 fatty acids.

15. The method of claim 14, wherein: The long-chain fatty acid and the second long-chain fatty acid are C16 fatty acid or C18 fatty acid.

16. The method of claim 14, wherein: The long chain fatty acid is palmitic acid, and the second long chain fatty acid is oleic acid, and the compound of Formula I is 1,3-oleyl-2-palmitoylglycerol.

17. The method of claim 16, further comprising providing a sn-1,3 selective lipase; contacting the sn-1,3 selective lipase with tripalmitin and oleic acid, wherein the contacting the sn-1,3 selective lipase with tripalmitin and oleic acid and the contacting the sn-2 selective lipase with triolein and palmitic acid are performed in a reactor.

18. The method of claim 14, wherein: The long chain fatty acid is oleic acid, and the second long chain fatty acid is stearic acid, and the compound of formula I is 1,3-distearoyl-2-oleoyl-glycerol.

19. The method according to any one of claims 9 to 18, wherein: Providing the sn-2 selective lipase includes expressing the corresponding nucleotide sequence in a host.

20. An isolated sn-2 selective lipase, the sn-2 selective lipase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:22 (CL20), SEQ ID NO:82 (CL20), SEQ ID NO:30 (CL28), SEQ ID NO:90 (CL28), SEQ ID NO:33 (CL31), SEQ ID NO:93 (CL31), SEQ ID NO:21 (CL19), SEQ ID NO:81 (CL19), SEQ ID NO:23 (CL21), SEQ ID NO:83 (CL21), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:41 (CL39), SEQ ID NO:101 (CL39), SEQ ID NO:15 (CL13), SEQ ID NO:75 (CL13), SEQ ID NO:40 (CL38), SEQ ID NO:100 (CL38), SEQ ID NO:46 (CL44), SEQ ID NO:47 (CL45), SEQ ID NO:48 (CL46), SEQ ID NO:49 (CL50), SEQ ID NO:50 (CL51), SEQ ID NO:51 (CL52), SEQ ID NO:52 (CL53), SEQ ID NO:53 (CL54), SEQ ID NO:54 (CL55), SEQ ID NO:55 (CL56), SEQ ID NO:56 (CL57), SEQ ID NO:57 (CL58), SEQ ID NO:58 (CL59), SEQ ID NO: NO:106(CL44), SEQ ID NO:26(CL24), SEQ ID NO:86(CL24), SEQ ID NO:47(CL45), SEQ ID NO:107(CL45), SEQ ID NO:17(CL15), SEQ ID NO:77(CL15), SEQ ID NO:44(CL42), SEQ ID NO:104 (CL42), SEQ ID NO:51 (CL49), SEQ ID NO:111 (CL49), SEQ ID NO:56 (CL54) and SEQ ID NO:116 (CL54).

21. The isolated sn-2 selective lipase of claim 20, consisting essentially of said amino acid sequence, preferably said lipase consists of said amino acid sequence.

22. The isolated sn-2 selective lipase of claim 20 or 21, wherein The amino acid sequence is selected from the group consisting of SEQ ID NO: 23 (CL21), SEQ ID NO: 83 (CL21), SEQ ID NO: 22 (CL20), SEQ ID NO: 82 (CL20), SEQ ID NO: 30 (CL28), SEQ ID NO: 90 (CL28), SEQ244917 1SGCN ID NO:44(CL42), SEQ ID NO:104(CL42), SEQ ID NO:15(CL13), SEQ ID NO:75(CL13), SEQ ID NO:47(CL45), SEQ ID NO:107(CL45), SEQ ID NO:33(CL31), SEQ ID NO:93(CL31), SEQ ID NO:21 (CL19), SEQ ID NO:81 (CL19), SEQ ID NO:25 (CL23), SEQ ID NO:85 (CL23), SEQ ID NO:41 (CL39) and SEQ ID NO:101 (CL39).

23. The lipase according to any one of claims 20 to 22, comprising a purification tag, wherein the purification tag is bound to the N-terminus or C-terminus of the amino acid sequence, preferably the N-terminus.